Patent Issued for Neutralizing antibodies to the avb8 integrin complex for immunotherapy (USPTO 12110334).

A patent has been issued for neutralizing antibodies to the avb8 integrin complex for immunotherapy by inventors from the University of California. The patent focuses on antibodies that specifically bind human avb8 and block the binding of TGFb peptide to avb8, potentially offering new avenues for immunotherapy. The patent details the specific amino acid sequences and regions targeted by the antibodies, as well as methods for detecting the presence of human avb8 in samples, including formalin-fixed samples and tumors. [Extracted from the article]